Magnetoferritin: Characterization of a novel superparamagnetic MR contrast agent

A protein‐encaged superparamagnetic iron oxide has been developed and characterized by using horse spleen apoferritin as a novel bioreactive environment. The roughly spherical magnetoferritin molecules, 120 Å in diameter, are composed of a monocrystalline maghemite or magnetite core 73 Å ± 14 in diameter. Except for the additional presence of iron‐rich molecules of higher molecular weight, the appearance and molecular weight (450 kd) of magnetoferritin are identical to that of natural ferritin; the molecules are externally indistinguishable from their precursor, with a pI (isoelectric point) in the range 4.3–4.6. The measured magnetic moment of the superparamagnetic cores is 13,200 Bohr magnetons per molecule, with T1 and T2 relaxivities (r1 and r2) of 8 and 175 L‐mmol−1 (Fe)‐sec−1, respectively, at body temperature and clinical field strengths. The unusually high r2/r1 ratio of 22 is thought to arise from ideal core composition, with no evidence of crystalline paramagnetic inclusions. T2 relaxation enhancement can be well correlated to the field‐dependent molecular magnetization, as given by the Langevin magnetization function, raised to a power in the range 1.4–1.6. With its nanodimensional biomimetic protein cage as a rigid, convenient matrix for complexing a plethora of bioactive substances, magnetoferritin may provide a novel template for specific targeting of selected cellular sites.

[1]  P. Arosio,et al.  On ferritin heterogeneity. Further evidence for heteropolymers. , 1978, The Journal of biological chemistry.

[2]  J. Hainfeld,et al.  Uranium-loaded apoferritin with antibodies attached: molecular design for uranium neutron-capture therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[3]  S. Mann Dalton perspectives. Biomineralization: the hard part of bioinorganic chemistry! , 1993 .

[4]  S. H. Koenig,et al.  Relaxometry of ferritin solutions and the influence of the Fe3+ core ions , 1986, Magnetic resonance in medicine.

[5]  R. Weissleder,et al.  Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. , 1990, Radiology.

[6]  R. Molday,et al.  Immunospecific ferromagnetic iron-dextran reagents for the labeling and magnetic separation of cells. , 1982, Journal of immunological methods.

[7]  Stephen Mann,et al.  Synthesis of inorganic nanophase materials in supramolecular protein cages , 1991, Nature.

[8]  Irving E. Dayton,et al.  Encyclopaedic Dictionary of Physics , 1964 .

[9]  P. Arosio,et al.  Expression and structural and functional properties of human ferritin L-chain from Escherichia coli. , 1989, Biochemistry.

[10]  J A Frank,et al.  Frequency dependence of MR relaxation times II. Iron oxides , 1993, Journal of magnetic resonance imaging : JMRI.

[11]  E. Verwey,et al.  Physical Properties and Cation Arrangement of Oxides with Spinel Structures I. Cation Arrangement in Spinels , 1947 .

[12]  R. Cortese,et al.  Characterization of human ferritin H chain synthetized in Escherichia coli. , 1987, Gene.

[13]  S. Mann,et al.  Crystallization at Inorganic-organic Interfaces: Biominerals and Biomimetic Synthesis , 1993, Science.

[14]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[15]  P. Arosio,et al.  Production and characterization of recombinant heteropolymers of human ferritin H and L chains. , 1993, The Journal of biological chemistry.

[16]  A. Roch,et al.  Transverse relaxivity of particulate MRI contrast media: From theories to experiments , 1991, Magnetic resonance in medicine.

[17]  P. Fitzpatrick,et al.  Human isoferritins in normal and disease states. , 1977, Seminars in hematology.

[18]  L. Josephson,et al.  The effects of iron oxides on proton relaxivity. , 1988, Magnetic resonance imaging.

[19]  D. Rice,et al.  Ferritin: design and formation of an iron-storage molecule. , 1984, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[20]  D. Dunlop,et al.  Magnetic Properties of Minerals , 1994 .

[21]  G. Peterson,et al.  A simplification of the protein assay method of Lowry et al. which is more generally applicable. , 1977, Analytical biochemistry.

[22]  P. Harrison The structure of apoferritin: molecular size, shape and symmetry from x-ray data. , 1963, Journal of molecular biology.

[23]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[24]  W. V. Shaw,et al.  Solving the structure of human H ferritin by genetically engineering intermolecular crystal contacts , 1991, Nature.

[25]  J. Drysdale,et al.  Isoelectric points of proteins: a table. , 1978, Analytical biochemistry.

[26]  P. C. Rieke,et al.  Innovative materials processing strategies: a biomimetic approach. , 1992, Science.

[27]  P. Harrison,et al.  Incorporation and release of inorganic phosphate in horse spleen ferritin. , 1978, The Biochemical journal.

[28]  R Weissleder,et al.  Monocrystalline iron oxide nanocompounds (MION): Physicochemical properties , 1993, Magnetic resonance in medicine.

[29]  John C. Gore,et al.  Studies of diffusion in random fields produced by variations in susceptibility , 1988 .

[30]  S. Mann,et al.  Magnetoferritin: in vitro synthesis of a novel magnetic protein. , 1992, Science.

[31]  P. Harrison,et al.  Influence of site-directed modifications on the formation of iron cores in ferritin. , 1991, Journal of molecular biology.

[32]  G. Chiro,et al.  T1 and t2 of ferritin at different field strengths: effect on mri , 1992, Magnetic resonance in medicine.

[33]  Y. Niitsu,et al.  Mechanisms for the formation of ferritin oligomers. , 1973, Biochemistry.

[34]  S. H. Koenig,et al.  Transverse relaxation of solvent protons induced by magnetized spheres: Application to ferritin, erythrocytes, and magnetite , 1987, Magnetic resonance in medicine.